Literature DB >> 26355086

Y-Box Binding Protein 1 Stabilizes Hepatitis C Virus NS5A via Phosphorylation-Mediated Interaction with NS5A To Regulate Viral Propagation.

Wei-Ting Wang1, Tsung-Yuan Tsai2, Chi-Hong Chao1, Bo-Ying Lai1, Yan-Hwa Wu Lee3.   

Abstract

UNLABELLED: Replication of hepatitis C virus (HCV) is dependent on virus-encoded proteins and numerous cellular factors. DDX3 is a well-known host cofactor of HCV replication. In this study, we investigated the role of a DDX3-interacting protein, Y-box binding protein 1 (YB-1), in the HCV life cycle. Both YB-1 and DDX3 interacted with the viral nonstructural protein NS5A. During HCV infection, YB-1 partially colocalized with NS5A and the HCV replication intermediate double-stranded RNA (dsRNA) in HCV-infected Huh-7.5.1 cells. Despite sharing the same interacting partners, YB-1 participated in HCV RNA replication but was dispensable in steady-state HCV RNA replication, different from the action of DDX3. Moreover, knockdown of YB-1 in HCV-infected cells prevented infectious virus production and reduced the ratio of hyperphosphorylated (p58) to hypophosphorylated (p56) forms of NS5A, whereas DDX3 silencing did not affect the ratio of the p58 and p56 phosphoforms of NS5A. Interestingly, silencing of YB-1 severely reduced NS5A protein stability in NS5A-ectopically expressing, replicon-containing, and HCV-infected cells. Furthermore, mutations of serine 102 of YB-1 affected both YB-1-NS5A interaction and NS5A-stabilizing activity of YB-1, indicating that this Akt phosphorylation site of YB-1 plays an important role in stabilizing NS5A. Collectively, our results support a model in which the event of YB-1 phosphorylation-mediated interaction with NS5A results in stabilizing NS5A to sustain HCV RNA replication and infectious HCV production. Overall, our study may reveal a new aspect for the development of novel anti-HCV drugs. IMPORTANCE: Chronic hepatitis C virus (HCV) infection induces liver cirrhosis and hepatocellular carcinoma. The viral nonstructural protein NS5A co-opting various cellular signaling pathways and cofactors to support viral genome replication and virion assembly is a new strategy for anti-HCV drug development. NS5A phosphorylation is believed to modulate switches between different stages of the HCV life cycle. In this study, we identified the cellular protein YB-1 as a novel NS5A-interacting protein. YB-1 is a multifunctional protein participating in oncogenesis and is an oncomarker of hepatocellular carcinoma (HCC). We found that YB-1 protects NS5A from degradation and likely regulates NS5A phosphorylation through its phosphorylation-dependent interaction with NS5A, which might be controlled by HCV-induced signaling pathways. Our observations suggest a model in which HCV modulates NS5A level and the ratio of the p58 and p56 phosphoforms for efficient viral propagation via regulation of cellular signaling inducing YB-1 phosphorylation. Our finding may provide new aspects for developing novel anti-HCV drugs.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26355086      PMCID: PMC4645663          DOI: 10.1128/JVI.01513-15

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  89 in total

Review 1.  Hepatitis C virus replication cycle.

Authors:  Ralf Bartenschlager; Francois-Loic Cosset; Volker Lohmann
Journal:  J Hepatol       Date:  2010-06-01       Impact factor: 25.083

2.  eIF2A mediates translation of hepatitis C viral mRNA under stress conditions.

Authors:  Joon Hyun Kim; Sung Mi Park; Ji Hoon Park; Sun Ju Keum; Sung Key Jang
Journal:  EMBO J       Date:  2011-05-10       Impact factor: 11.598

3.  Upregulated c-myc expression in multiple myeloma by internal ribosome entry results from increased interactions with and expression of PTB-1 and YB-1.

Authors:  L C Cobbold; L A Wilson; K Sawicka; H A King; A V Kondrashov; K A Spriggs; M Bushell; A E Willis
Journal:  Oncogene       Date:  2010-03-01       Impact factor: 9.867

4.  Hepatitis C virus controls interferon production through PKR activation.

Authors:  Noëlla Arnaud; Stéphanie Dabo; Patrick Maillard; Agata Budkowska; Katerina I Kalliampakou; Penelope Mavromara; Dominique Garcin; Jacques Hugon; Anne Gatignol; Daisuke Akazawa; Takaji Wakita; Eliane F Meurs
Journal:  PLoS One       Date:  2010-05-11       Impact factor: 3.240

5.  Molecular decoy to the Y-box binding protein-1 suppresses the growth of breast and prostate cancer cells whilst sparing normal cell viability.

Authors:  Jennifer H Law; Yvonne Li; Karen To; Michelle Wang; Arezoo Astanehe; Karen Lambie; Jaspreet Dhillon; Steven J M Jones; Martin E Gleave; Connie J Eaves; Sandra E Dunn
Journal:  PLoS One       Date:  2010-09-10       Impact factor: 3.240

6.  Recruitment and activation of a lipid kinase by hepatitis C virus NS5A is essential for integrity of the membranous replication compartment.

Authors:  Simon Reiss; Ilka Rebhan; Perdita Backes; Ines Romero-Brey; Holger Erfle; Petr Matula; Lars Kaderali; Marion Poenisch; Hagen Blankenburg; Marie-Sophie Hiet; Thomas Longerich; Sarah Diehl; Fidel Ramirez; Tamas Balla; Karl Rohr; Artur Kaul; Sandra Bühler; Rainer Pepperkok; Thomas Lengauer; Mario Albrecht; Roland Eils; Peter Schirmacher; Volker Lohmann; Ralf Bartenschlager
Journal:  Cell Host Microbe       Date:  2011-01-20       Impact factor: 21.023

7.  Hepatitis C virus stimulates the phosphatidylinositol 4-kinase III alpha-dependent phosphatidylinositol 4-phosphate production that is essential for its replication.

Authors:  Kristi L Berger; Sean M Kelly; Tristan X Jordan; Michael A Tartell; Glenn Randall
Journal:  J Virol       Date:  2011-06-22       Impact factor: 5.103

8.  Antiviral stilbene 1,2-diamines prevent initiation of hepatitis C virus RNA replication at the outset of infection.

Authors:  Pablo Gastaminza; Suresh M Pitram; Marlene Dreux; Larissa B Krasnova; Christina Whitten-Bauer; Jiajia Dong; Josan Chung; Valery V Fokin; K Barry Sharpless; Francis V Chisari
Journal:  J Virol       Date:  2011-03-23       Impact factor: 5.103

9.  Zinc mesoporphyrin induces rapid proteasomal degradation of hepatitis C nonstructural 5A protein in human hepatoma cells.

Authors:  Weihong Hou; Qing Tian; Jianyu Zheng; Herbert L Bonkovsky
Journal:  Gastroenterology       Date:  2009-11-10       Impact factor: 22.682

10.  Heat shock protein 72 is associated with the hepatitis C virus replicase complex and enhances viral RNA replication.

Authors:  Yin-Ju Chen; Yu-Hsuan Chen; Lu-Ping Chow; Ya-Hui Tsai; Pei-Hong Chen; Chi-Ying F Huang; Wei-Tzu Chen; Lih-Hwa Hwang
Journal:  J Biol Chem       Date:  2010-07-02       Impact factor: 5.157

View more
  5 in total

1.  RNA helicase DDX3 maintains lipid homeostasis through upregulation of the microsomal triglyceride transfer protein by interacting with HNF4 and SHP.

Authors:  Tsung-Yuan Tsai; Wei-Ting Wang; Hao-Kang Li; Wei-Ju Chen; Yu-Hong Tsai; Chi-Hong Chao; Yan-Hwa Wu Lee
Journal:  Sci Rep       Date:  2017-01-27       Impact factor: 4.379

Review 2.  Strategies for Success. Viral Infections and Membraneless Organelles.

Authors:  Aracelly Gaete-Argel; Chantal L Márquez; Gonzalo P Barriga; Ricardo Soto-Rifo; Fernando Valiente-Echeverría
Journal:  Front Cell Infect Microbiol       Date:  2019-10-11       Impact factor: 5.293

Review 3.  DEAD-box RNA Helicase DDX3: Functional Properties and Development of DDX3 Inhibitors as Antiviral and Anticancer Drugs.

Authors:  Marina K Kukhanova; Inna L Karpenko; Alexander V Ivanov
Journal:  Molecules       Date:  2020-02-24       Impact factor: 4.411

Review 4.  mRNA Post-Transcriptional Regulation by AU-Rich Element-Binding Proteins in Liver Inflammation and Cancer.

Authors:  Dobrochna Dolicka; Cyril Sobolewski; Marta Correia de Sousa; Monika Gjorgjieva; Michelangelo Foti
Journal:  Int J Mol Sci       Date:  2020-09-11       Impact factor: 5.923

Review 5.  Hepatitis C Viral Replication Complex.

Authors:  Hui-Chun Li; Chee-Hing Yang; Shih-Yen Lo
Journal:  Viruses       Date:  2021-03-22       Impact factor: 5.048

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.